罗沙司他治疗肾性贫血患者早期临床疗效研究
Early Clinical Efficacy Study of Roxadustat in the Treatment of Patients with Renal Anemia
DOI: 10.12677/ACM.2022.12121638, PDF,    科研立项经费支持
作者: 王加如*：山东第一医科大学(山东省医学科学院)，山东 济南；蔄瑜琳, 周忠启#：临沂市人民医院肾脏内科，山东 临沂；张静静：锦州医科大学，辽宁 锦州
关键词: 慢性肾脏病；贫血；罗沙司他；网织红细胞；Chronic Kidney Disease； Anemia； Rosasta； Reticulocyte
摘要: 目的：观察罗沙司他早期对肾性贫血患者促红细胞生成素(EPO)及网织红细胞参数影响，分析其在改善肾性贫血方面的有效性。方法：选取符合研究标准的受试者30名，在服药前及服药7天后分别抽取静脉血监测EPO及网织红细胞计数。结果：服药后患者EPO及网织红细胞计数显著升高，与服药前相比均有统计学意义P < 0.05。结论：罗沙司他可以在用药早期通过升高EPO浓度，加快成熟红细胞的增殖、分化，进一步改善肾性贫血患者贫血症状。
Abstract: Objective: To observe the effect of rosastat on erythropoietin (EPO) and reticulocyte parameters in patients with renal anemia in the early stage, and analyze its effectiveness in improving renal anemia. Methods: Thirty subjects who met the study criteria were selected, and venous blood samples were taken before and 7 days after administration to monitor EPO and reticulocyte count. Results: The EPO and reticulocyte count of the patients increased significantly after taking the drug, which was statistically significant compared with that before taking the drug (P < 0.05). Conclusion: Rosalistat can accelerate the proliferation and differentiation of mature red blood cells by increasing EPO concentration at the early stage of administration, and further improve the anemia symptoms of patients with renal anemia.
文章引用：王加如, 蔄瑜琳, 张静静, 周忠启. 罗沙司他治疗肾性贫血患者早期临床疗效研究[J]. 临床医学进展, 2022, 12(12): 11362-11367. https://doi.org/10.12677/ACM.2022.12121638

参考文献

[1] Zhang, L., Fang, W., Wang, L., Wang, W., Liu, B., Jian, L., Chen, M., Qiang, H., Liao, Y. and Yu, X. (2012) Prevalence of Chronic Kidney Disease in China: A Cross-Sectional Survey. The Lancet, 380, 214-214. [Google Scholar] [CrossRef] 
[2] 傅晓岑, 任红, 陈楠. 肾性贫血的治疗研究[J]. 中国血液净化, 2022, 21(1): 6-9.
[3] 王莉君, 袁伟杰. 关于肾性贫血治疗相关指南与共识回顾[J]. 中国血液净化, 2018, 17(1): 1-5.
[4] 陈楠. 罗沙司他在慢性肾脏病患者肾性贫血治疗中的应用[J]. 中华内科杂志, 2019, 58(12): 919-920.
[5] 张倩, 巴应贵. 肾性贫血发生机制的研究现状[J]. 临床医学进展, 2021, 11(5): 2251-2256. [Google Scholar] [CrossRef] 
[6] Souma, T., Norio, S. and Yamamoto, M. (2015) Renal Eryth-ropoietin-Producing Cells in Health and Disease. Frontiers in Physiology, 6, Article 167. [Google Scholar] [CrossRef] [PubMed]
[7] 李伟英, 陈崴. 肾性贫血铁代谢指标的评估、判读及应用[J]. 中国实用内科杂志, 2020, 40(12): 1010-1014.
[8] Rodriguez, R., Jung, C.L., Gabayan, V., Deng, J.C., Ganz, T., Nemeth, E., Bulut, Y. and Roy, C.R. (2014) Hepcidin Induction by Pathogens and Pathogen-Derived Molecules Is Strongly Dependent on Interleukin-6. Infection & Immunity, 82, 745-752. [Google Scholar] [CrossRef] 
[9] Kautz, L., Jung, G., Valore, E.V., Rivella, S., Nemeth, E. and Ganz, T. (2014) Identification of Erythroferrone as an Erythroid Regulator of Iron Metabolism. Nature Genetics, 46, 678-684. [Google Scholar] [CrossRef] [PubMed]
[10] 谭娉婵, 罗良海, 邓卫, 谭晓军. 罗沙司他与重组人促红细胞生成素治疗血液透析肾性贫血临床疗效的比较研究[J]. 临床合理用药杂志, 2021, 14(18): 5-8.
[11] 白瑞, 张蕾. 低氧诱导因子脯氨酰羟化酶抑制剂治疗肾性贫血的研究进展[J]. 实用医药杂志, 2021, 38(3): 272-276.
[12] 郝传明, 李菁. 脯氨酰羟化酶抑制剂治疗肾性贫血: 全新途径, 全新挑战[J]. 肾脏病与透析肾移植杂志, 2021, 30(3): 203-204.
[13] Liu, Q., Davidoff, O., Niss, N. and Haase, V.H. (2012) Hypoxia-Inducible Factor Regulates Hepcidin via Erythropoietin-Induced Erythropoiesis. Journal of Clinical Investigation, 122, 4635-4644. [Google Scholar] [CrossRef] 
[14] 徐巧玲, 朱翊, 何笑荣, 张田, 金鹏飞. 罗沙司他治疗肾性贫血安全性的研究进展[J]. 中国医院用药评价与分析, 2022, 22(6): 761-764+768.
[15] 徐丹, 冯霞, 钟询龙, 王若伦. 罗沙司他治疗肾性贫血效果的影响因素分析[J]. 中国医院药学杂志, 2022, 42(7): 732-735.
[16] Provenzano, R., Tumlin, J., Zabaneh, R., Chou, J., Hemmerich, S., Neff, T.B. and Yu, K.H.P. (2020) Oral Hypoxia-Inducible Factor Prolyl Hy-droxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients. The Journal of Clinical Pharma-cology, 60, 1432-1440. [Google Scholar] [CrossRef] [PubMed]
[17] Dhillon, S. (2019) Roxadustat: First Global Ap-proval. Drugs, 79, 563-572. [Google Scholar] [CrossRef] [PubMed]
[18] Provenzano, R., Besarab, A., Wright, S., Dua, S., Zeig, S., Nguyen, P., Poole, L., Saikali, K.G., Saha, G. and Hemmerich, S. (2016) Roxadustat (FG-4592) versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study. American Journal of Kidney Diseases, 67, 912-924. [Google Scholar] [CrossRef] [PubMed]
[19] Vaziri, N.D. and Zhou, X.J. (2009) Potential Mechanisms of Adverse Outcomes in Trials of Anemia Correction with Erythropoietin in Chronic Kidney Disease. Nephrology Dialysis Transplantation, 24, 1082-1088. [Google Scholar] [CrossRef] [PubMed]
[20] 李绵绵, 李芳, 余玲玲, 陈小剑. 新型网织红细胞参数在贫血早期诊断中的价值[J]. 中国卫生检验杂志, 2019, 29(11): 1289-1291.
[21] 李小龙, 陶洪群, 王薇薇, 徐斐, 黄小芳, 王赛芳, 刘欢乐, 王金果, 刘晖. 网织红细胞血红蛋白含量在缺铁性贫血诊断治疗中的价值[J]. 中华血液学杂志, 2015, 36(8): 695-697.
[22] Yaribeygi, H., Butler, A.E., Barreto, G.E. and Sahebkar, A. (2019) Antioxidative Potential of Antidiabetic Agents: A Possible Protective Mechanism against Vascular Complications in Diabetic Patients. Journal of Cellular Physiology, 234, 2436-2446. [Google Scholar] [CrossRef] [PubMed]
[23] 双淑贞. 促红细胞生成素对糖尿病肾性贫血患者网织红细胞参数的影响[J]. 当代医学, 2016, 22(31): 145-146.
[24] 夏坚明, 徐玢, 蒋伟光. 促红细胞生成素治疗糖尿病肾性贫血的网织红细胞参数的变化观察[J]. 中国误诊学杂志, 2008, 8(1): 35-36.
[25] Ogawa, C., Tsuchiya, K., Tomosugi, N. and Maeda, K. (2020) A Hypoxia-Inducible Factor Stabilizer Improves Hematopoiesis and Iron Metabolism Early after Administration to Treat Anemia in Hemodialysis Patients. International Journal of Molecular Sciences, 21, Article 7153. [Google Scholar] [CrossRef] [PubMed]

为你推荐